| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(00)00516-8 |
| P698 | PubMed publication ID | 11257347 |
| P50 | author | Charles Edward Rupprecht | Q60394248 |
| P2093 | author name string | Hanlon CA | |
| Niezgoda M | |||
| Morrill PA | |||
| P2860 | cites work | Development of Orphan Vaccines: An Industry Perspective | Q27487916 |
| Rabies--risk of exposure and current trends in prevention of human cases | Q33589219 | ||
| A review of the economics of the prevention and control of rabies. Part 1: Global impact and rabies in humans | Q33645580 | ||
| A review of the economics of the prevention and control of rabies. Part 2: Rabies in dogs, livestock and wildlife | Q33645603 | ||
| Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies | Q35814688 | ||
| Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus | Q36350202 | ||
| Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system | Q37141934 | ||
| Animal models in the pathogenesis and treatment of rabies. | Q39550228 | ||
| Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis | Q41019444 | ||
| Development of human monoclonal antibodies to rabies | Q41439303 | ||
| A Rabies-Specific Human Monoclonal Antibody That Protects Mice Against Lethal Rabies | Q41662869 | ||
| Incidence of reactions to antirabies horse serum | Q41916316 | ||
| Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein | Q42812165 | ||
| The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. | Q45744398 | ||
| Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. | Q45829999 | ||
| Failure of rabies postexposure treatment in Thailand | Q69606301 | ||
| Mass human exposure to rabies in New Hampshire: exposures, treatment, and cost | Q71270848 | ||
| Failure of postexposure treatment of rabies in children | Q71608291 | ||
| Additional reports of failure to respond to treatment after rabies exposure in Thailand | Q74460219 | ||
| Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine | Q77429475 | ||
| Current recommendations for the prophylaxis and treatment of rabies | Q77601611 | ||
| Use of hyperimmune anti-rabies serum concentrates in experimental rabies | Q80667155 | ||
| P433 | issue | 17-19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rabies | Q39222 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 2273-2279 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | The incurable wound revisited: progress in human rabies prevention? | |
| P478 | volume | 19 |
| Q28601417 | Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis |
| Q47387628 | Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent model |
| Q24811640 | Emergency vaccination of rabies under limited resources -- combating or containing? |
| Q37635370 | Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals |
| Q81373851 | Failures of post-exposure rabies prophylaxis |
| Q56741242 | Four Thousand Years of Concepts Relating to Rabies in Animals and Humans, Its Prevention and Its Cure |
| Q34296691 | Generation and characterization of neutralizing human recombinant antibodies against antigenic site II of rabies virus glycoprotein |
| Q40180565 | Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates |
| Q52663792 | In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity. |
| Q40300404 | Injecting rabies immunoglobulin (RIG) into wounds only: A significant saving of lives and costly RIG. |
| Q24531953 | Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants |
| Q38006132 | Passive immunity in the prevention of rabies. |
| Q34408085 | Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice |
| Q42734901 | Public health surveillance for Australian bat lyssavirus in Queensland, Australia, 2000-2001. |
| Q56751593 | Rabies |
| Q40640587 | Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers |
| Q33338456 | Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab). |
| Q34764816 | Rabies re-examined |
| Q33153644 | Renal involvement in human rabies: clinical manifestations and autopsy findings of nine cases from northeast of Brazil |
Search more.